Bio-Path Holdings Unveils Preclinical Trials of BP1001-A as a Possible Solution for Obesity in Patients with Type 2 Diabetes for Improved Insulin Sensitivity

Bio-Path Holdings NASDAQ: BPTH, Inc., a pioneering biotech firm, has announced promising results from preclinical studies of its latest development, BP1001-A, a targeted nucleic acid cancer drug. The preclinical trials show BP1001-A could potentially provide a new treatment for obesity and its related metabolic diseases in patients with Type 2 diabetes.

BP1001-A’s unique ability to decrease growth factor receptor-bound protein 2 (Grb2) expression, which in turn boosts insulin sensitivity and reduces blood glucose levels, has been proven in these initial studies. This scientific breakthrough could assist in controlling insulin signaling and thus managing blood glucose levels in Type 2 diabetes patients.

The initial research findings revealed that BP1001-A was able to reduce Grb2 protein expression in myoblast cells, consequently affecting insulin signaling and demonstrating its potential as a unique treatment for obesity in patients with Type 2 diabetes. The tests further verified that BP1001-A has the potential to enhance insulin-induced metabolic activities through its ability to influence the insulin/phosphoinositol-3 kinase (PI3K)/AKT pathway, resulting in increased insulin sensitivity.

Bio-Path’s President and Chief Executive Officer, Peter H. Nielsen, expressed his enthusiasm about the remarkable progress made in advancing BP1001-A as a potential treatment. According to Mr. Nielsen, the consistent failure of popular weight loss medications calls for a novel approach in treating Type 2 diabetes patients.

Bio-Path has commenced animal studies to verify the effectiveness of BP1001-A and plans to initiate its first human Phase 1 clinical trial in 2025. This will help to further confirm safety, ascertain pharmacokinetics, and establish dosing for potential pivotal trials.